Establishment Labs Net Income Over Time
| ESTA Stock | USD 73.20 0.34 0.46% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Establishment Labs Performance and Establishment Labs Correlation. Establishment | Build AI portfolio with Establishment Stock |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Establishment Labs. Projected growth potential of Establishment fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Establishment Labs assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (2.84) | Revenue Per Share | Quarterly Revenue Growth 0.337 | Return On Assets | Return On Equity |
The market value of Establishment Labs is measured differently than its book value, which is the value of Establishment that is recorded on the company's balance sheet. Investors also form their own opinion of Establishment Labs' value that differs from its market value or its book value, called intrinsic value, which is Establishment Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Establishment Labs' market value can be influenced by many factors that don't directly affect Establishment Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Establishment Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Establishment Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Establishment Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Net Income Analysis
Compare Establishment Labs and related stocks such as CONMED, Azenta Inc, and UFP Technologies Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CNMD | 700 K | 752 K | 40.5 M | 35.9 M | 32.2 M | 30.5 M | 14.7 M | 55.5 M | 40.9 M | 28.6 M | 9.5 M | 62.5 M | (80.6 M) | 64.5 M | 132.4 M | 47.1 M | 24.4 M |
| AZTA | 1.5 M | 136.8 M | (2.2 M) | 4.5 M | 14.2 M | (69.5 M) | 62.6 M | 116.6 M | 28.8 M | 64.9 M | 110.7 M | (429 M) | (14.3 M) | (164.9 M) | (55.8 M) | (64.1 M) | (67.3 M) |
| UFPT | 200 K | 10.3 M | 10.9 M | 11.3 M | 7.6 M | 7.6 M | 8 M | 9.2 M | 14.3 M | 19.8 M | 13.4 M | 15.9 M | 41.8 M | 44.9 M | 59 M | 67.8 M | 71.2 M |
| NVCR | (77.4 M) | (77.4 M) | (77.4 M) | (77.4 M) | (80.7 M) | (111.6 M) | (131.8 M) | (61.7 M) | (63.6 M) | (7.2 M) | 19.8 M | (58.4 M) | (92.5 M) | (207 M) | (168.6 M) | (151.8 M) | (144.2 M) |
| ZYME | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (12.9 M) | (19.2 M) | (33.8 M) | (10.4 M) | (36.6 M) | (145.4 M) | (180.6 M) | (211.8 M) | 124.3 M | (118.7 M) | (122.7 M) | (110.4 M) | (115.9 M) |
| KMTS | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (34.1 M) | (84.2 M) | (84.2 M) | (94.1 M) | (113.8 M) | (102.4 M) | (107.6 M) |
| AHCO | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (690) | 2.1 M | (21.3 M) | (161.6 M) | 156.2 M | 69.3 M | (678.9 M) | 90.4 M | 81.4 M | 85.4 M |
| TDOC | (6 M) | (6 M) | (6 M) | (6 M) | (17 M) | (58 M) | (74.2 M) | (106.8 M) | (97.1 M) | (98.9 M) | (485.1 M) | (428.8 M) | (13.7 B) | (220.4 M) | (1 B) | (901.1 M) | (946.2 M) |
| SSII | (66.0) | (66.0) | (66.0) | (66.0) | (66.0) | (66.0) | (485 K) | (1 M) | (960.3 K) | (3.4 M) | (1.1 M) | (1.5 M) | (5.6 M) | (20.9 M) | (19.2 M) | (17.2 M) | (16.4 M) |
| SYRE | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (11.3 M) | (21.7 M) | (27.2 M) | (44.3 M) | (78.3 M) | (80.9 M) | (65.8 M) | (83.8 M) | (338.8 M) | (208 M) | (187.2 M) | (177.9 M) |
Establishment Labs and related stocks such as CONMED, Azenta Inc, and UFP Technologies Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Establishment Labs financial statement analysis. It represents the amount of money remaining after all of Establishment Labs Holdings operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Establishment Labs Holdings | ESTA |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | Building B23 and |
| Exchange | NASDAQ Exchange |
USD 73.2
Check out Establishment Labs Performance and Establishment Labs Correlation. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Establishment Labs technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.